Solventum (NYSE:SOLV) Posts Earnings Results, Beats Estimates By $0.11 EPS

Solventum (NYSE:SOLV) posted its quarterly earnings results on Thursday. The company reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.11, FiscalAI reports. Solventum had a return on equity of 25.09% and a net margin of 17.26%. The company had revenue of $1.95 billion during the quarter, compared to the consensus estimate of $1.93 billion. During the same quarter in the prior year, the company earned $1.50 EPS. The firm’s quarterly revenue was down 7.0% compared to the same quarter last year.

Here are the key takeaways from Solventum’s conference call:

• Q3 sales were $1.95 billion, down 7% reported and 2.8% organically, including a 630-basis-point headwind from the planned reversal of ERP-related advance orders. Management said normalized organic growth was about 4%; EPS was $1.45, including an estimated $0.35 impact from the timing reversal.
• Solventum raised its 2026 outlook, now expecting organic sales growth toward the high end of its 2.5%–3% range and EPS of $7.20–$7.30, up from $7.10–$7.20. Operating margin is expected toward the high end of its 22.2%–22.7% range.
• The company completed its largest ERP cutover and said its separation from 3M is more than 90% complete, with the remaining transition services expected to end by the close of 2027. A renegotiated supply agreement also removes a previously anticipated 100-basis-point gross-margin headwind beginning in 2027; management expects separation costs to step down, supporting free cash flow.
• Solventum is evaluating a sale or spin-off of Health Information Systems (HIS), with timing and structure still undecided. Management estimates the separation would cause about 400 basis points of annualized net operating margin dilution, though it expects to use proceeds first to pay down debt and then return most remaining proceeds to shareholders.
• Management highlighted growth opportunities from underpenetrated products, new launches, and acquisitions, including V.A.C. wound therapy and Acera. Acera grew 35% and had its best quarter on record, while the company said its combined-use clearance for Restrata and V.A.C. enables joint marketing.

Solventum Price Performance

Shares of SOLV traded up $4.11 during midday trading on Friday, hitting $91.28. 1,276,417 shares of the company traded hands, compared to its average volume of 1,303,126. The stock has a 50-day moving average of $87.75 and a 200-day moving average of $78.64. Solventum has a one year low of $62.38 and a one year high of $94.16. The firm has a market cap of $15.54 billion, a P/E ratio of 11.19, a PEG ratio of 1.30 and a beta of 0.69. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.02 and a quick ratio of 0.74.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Wells Fargo & Company increased their target price on shares of Solventum from $89.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Friday. Weiss Ratings raised shares of Solventum from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th. Piper Sandler restated an “overweight” rating and set a $110.00 price target (up from $105.00) on shares of Solventum in a research note on Friday. Mizuho set a $113.00 price objective on shares of Solventum in a report on Thursday, August 6th. Finally, UBS Group lifted their price objective on shares of Solventum from $95.00 to $101.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Ten analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $90.27.

Trending Headlines about Solventum

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Solventum reported third-quarter adjusted EPS of $1.45, above analysts’ $1.34 estimate, and revenue of $1.95 billion, ahead of expectations. The company raised its 2026 adjusted EPS outlook to $7.20–$7.30 and expects organic sales growth toward the high end of its 2.5%–3.0% range. Solventum Q3 financial results
• Positive Sentiment: Analysts lifted price targets: Piper Sandler raised its target to $110 and reaffirmed an Overweight rating; Wells Fargo raised its target to $95 while maintaining Equal Weight; and Jefferies raised its target to $98. Jefferies target change
• Positive Sentiment: The company said its separation from 3M is more than 90% complete, a milestone that may reduce uncertainty as the transition nears its conclusion. Solventum earnings and separation update
• Negative Sentiment: Revenue fell 7% year over year and organic sales declined 2.8%. Solventum attributed the organic decline partly to customers’ advance orders in the prior quarter ahead of the planned ERP system cutover; EPS was also below the $1.50 reported a year earlier. Solventum Q3 financial results

About Solventum

Solventum Corporation (NYSE: SOLV) is a global healthcare company that develops products and solutions intended to improve patient care, support healthcare professionals and enhance the efficiency of healthcare systems. Its offerings serve hospitals, clinics, dental practices, laboratories, manufacturers and other healthcare-related organizations.

The company’s portfolio includes medical and surgical products such as wound-care systems, dressings, skin-protection products, sterilization assurance products and solutions used in operating rooms.